ArcticZymes Technologies Completes Share Buyback to Support Employee Share Purchase Program

Tromsø, Norway, November 28th, 2025 - Reference is made to the stock exchange announcement published by ArcticZymes Technologies ASA (the "Company", OSE: AZT) on 25 November 2025 announcing the initiation of a share buyback program pursuant to the authorization granted by the Annual General Meeting held on 27 May 2025.

The share buyback program has now been completed. From and including 25 November 2025 to and including 28 November 2025, the Company has purchased a total of 31,365 own shares at an average price of NOK 22.5037 per share. Please see the attached table for further details.

Following completion of the program, the Company holds 31,365 own shares, equal to approx. 0.061 per cent of the total number of shares in the Company.

The repurchased shares will be used to settle obligations under the share-based incentive programs for employees and management where employees can acquire shares at 15% discount to the market price.

This information is made public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh — Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll — Tel +47 952 90187

ir@arcticzymes.com

About ArcticZymes Technologies ASA

Headquartered in Tromsø, Norway, *ArcticZymes Technologies ASA* is a publicly listed, leading provider of novel and high-quality enzymes for use in molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company develops and manufactures salt-active nucleases and other specialty enzymes inspired by the Arctic environment, enabling robust performance under demanding process conditions. ArcticZymes is certified to ISO 13485 and manufactures under relevant ICH GMP standards.
For more information, visit www.arcticzymes.com.